CH646414A5 - Purified pancreatic spasmolytic polypeptide, process for its isolation, and pharmaceutical composition - Google Patents

Purified pancreatic spasmolytic polypeptide, process for its isolation, and pharmaceutical composition Download PDF

Info

Publication number: CH646414A5
Authority: CH; Switzerland
Prior art keywords: cys; pro; ser; psp; polypeptide
Prior art date: 1979-09-11

Application number

CH681480A

Other languages

German (de)

English (en)

Inventor

Klavs Holger Jorgensen

Karin Damm Jorgensen

Lars Thim

Original Assignee

Novo Industri As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-09-11

Filing date

1980-09-10

Publication date

1984-11-30

1980-09-10 Application filed by Novo Industri As filed Critical Novo Industri As

1984-11-30 Publication of CH646414A5 publication Critical patent/CH646414A5/de

Links

238000000034 method Methods 0.000 title claims description 30
238000002955 isolation Methods 0.000 title claims description 3
108010056579 pancreatic spasmolytic polypeptide Proteins 0.000 title claims 4
239000008194 pharmaceutical composition Substances 0.000 title claims 4
230000008569 process Effects 0.000 title description 6
239000000243 solution Substances 0.000 claims description 25
108090000765 processed proteins & peptides Proteins 0.000 claims description 24
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 23
102000004196 processed proteins & peptides Human genes 0.000 claims description 22
230000000694 effects Effects 0.000 claims description 21
239000000203 mixture Substances 0.000 claims description 21
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
229920001184 polypeptide Polymers 0.000 claims description 20
239000002244 precipitate Substances 0.000 claims description 18
108090000623 proteins and genes Proteins 0.000 claims description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
102000051325 Glucagon Human genes 0.000 claims description 13
108060003199 Glucagon Proteins 0.000 claims description 13
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 13
229960004666 glucagon Drugs 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 12
239000006228 supernatant Substances 0.000 claims description 12
150000001413 amino acids Chemical class 0.000 claims description 10
239000011780 sodium chloride Substances 0.000 claims description 10
102000004877 Insulin Human genes 0.000 claims description 8
108090001061 Insulin Proteins 0.000 claims description 8
238000004587 chromatography analysis Methods 0.000 claims description 8
239000000284 extract Substances 0.000 claims description 8
229940125396 insulin Drugs 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 7
150000001450 anions Chemical class 0.000 claims description 7
210000004907 gland Anatomy 0.000 claims description 6
239000003960 organic solvent Substances 0.000 claims description 6
210000000496 pancreas Anatomy 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 6
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 5
150000001768 cations Chemical class 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
230000005176 gastrointestinal motility Effects 0.000 claims description 4
239000012452 mother liquor Substances 0.000 claims description 4
230000002378 acidificating effect Effects 0.000 claims description 3
238000001556 precipitation Methods 0.000 claims description 3
239000003755 preservative agent Substances 0.000 claims description 3
238000005185 salting out Methods 0.000 claims description 3
230000002048 spasmolytic effect Effects 0.000 claims description 3
239000008174 sterile solution Substances 0.000 claims description 3
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 2
239000002872 contrast media Substances 0.000 claims description 2
238000002425 crystallisation Methods 0.000 claims description 2
230000008025 crystallization Effects 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
238000000605 extraction Methods 0.000 claims description 2
230000002496 gastric effect Effects 0.000 claims description 2
230000004130 lipolysis Effects 0.000 claims description 2
230000000144 pharmacologic effect Effects 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims 3
239000000812 cholinergic antagonist Substances 0.000 claims 3
125000000539 amino acid group Chemical group 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
210000002460 smooth muscle Anatomy 0.000 claims 2
229930003347 Atropine Natural products 0.000 claims 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 1
208000007101 Muscle Cramp Diseases 0.000 claims 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 1
108010088411 Trefoil Factor-2 Proteins 0.000 claims 1
102100039172 Trefoil factor 2 Human genes 0.000 claims 1
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 1
230000001078 anti-cholinergic effect Effects 0.000 claims 1
230000002921 anti-spasmodic effect Effects 0.000 claims 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
239000002249 anxiolytic agent Substances 0.000 claims 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 1
229960000396 atropine Drugs 0.000 claims 1
150000001875 compounds Chemical class 0.000 claims 1
150000002148 esters Chemical class 0.000 claims 1
230000029142 excretion Effects 0.000 claims 1
201000001421 hyperglycemia Diseases 0.000 claims 1
230000035873 hypermotility Effects 0.000 claims 1
230000003472 neutralizing effect Effects 0.000 claims 1
230000001151 other effect Effects 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
239000000813 peptide hormone Substances 0.000 claims 1
230000002040 relaxant effect Effects 0.000 claims 1
108010013137 spasmolytic polypeptide Proteins 0.000 claims 1
208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 61
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
230000009268 pathologic speech processing Effects 0.000 description 60
238000005119 centrifugation Methods 0.000 description 20
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
102000004169 proteins and genes Human genes 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000003480 eluent Substances 0.000 description 8
239000000463 material Substances 0.000 description 8
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
238000005571 anion exchange chromatography Methods 0.000 description 7
239000000872 buffer Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
238000001962 electrophoresis Methods 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
229920005654 Sephadex Polymers 0.000 description 5
239000012507 Sephadex™ Substances 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
238000005277 cation exchange chromatography Methods 0.000 description 5
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
238000010828 elution Methods 0.000 description 4
235000019253 formic acid Nutrition 0.000 description 4
230000027119 gastric acid secretion Effects 0.000 description 4
239000000499 gel Substances 0.000 description 4
210000000936 intestine Anatomy 0.000 description 4
238000001155 isoelectric focusing Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
CFYIUBWVKZQDOG-UHFFFAOYSA-N 4-[[2-[[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-oxobutanoic acid Chemical compound C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(NC(=O)CNC(=O)CNC(=O)CCC(=O)O)CC1=CC=CC=C1 CFYIUBWVKZQDOG-UHFFFAOYSA-N 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
108090000919 Pyroglutamyl-Peptidase I Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000002775 capsule Substances 0.000 description 3
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
238000011534 incubation Methods 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
102000005157 Somatostatin Human genes 0.000 description 2
108010056088 Somatostatin Proteins 0.000 description 2
241000282887 Suidae Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
229960001380 cimetidine Drugs 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000006240 deamidation Effects 0.000 description 2
230000002183 duodenal effect Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
210000003405 ileum Anatomy 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000008991 intestinal motility Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
-1 lipid compounds Chemical class 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000004899 motility Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
229960001999 phentolamine Drugs 0.000 description 2
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 2
239000003531 protein hydrolysate Substances 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000002904 solvent Substances 0.000 description 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
229960000553 somatostatin Drugs 0.000 description 2
239000000725 suspension Substances 0.000 description 2
AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
108010075254 C-Peptide Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010065713 Gastric Fistula Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
102000045576 Lactoperoxidases Human genes 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
108010019160 Pancreatin Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
230000009858 acid secretion Effects 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960002028 atropine sulfate Drugs 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001839 endoscopy Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000000762 glandular Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
201000000079 gynecomastia Diseases 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
210000004923 pancreatic tissue Anatomy 0.000 description 1
229940055695 pancreatin Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000005086 pumping Methods 0.000 description 1
229940043131 pyroglutamate Drugs 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Reinforced Plastic Materials (AREA)

CH681480A 1979-09-11 1980-09-10 Purified pancreatic spasmolytic polypeptide, process for its isolation, and pharmaceutical composition CH646414A5 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB7931518		1979-09-11

Publications (1)

Publication Number	Publication Date
CH646414A5 true CH646414A5 (en)	1984-11-30

Family

ID=10507754

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH681480A CH646414A5 (en)	1979-09-11	1980-09-10	Purified pancreatic spasmolytic polypeptide, process for its isolation, and pharmaceutical composition

Country Status (15)

Country	Link
JP (1)	JPS609760B2 (sv)
AT (1)	AT373149B (sv)
AU (1)	AU537523B2 (sv)
BE (1)	BE885199A (sv)
CA (1)	CA1160624A (sv)
CH (1)	CH646414A5 (sv)
DE (1)	DE3034198A1 (sv)
DK (1)	DK380880A (sv)
ES (1)	ES494917A0 (sv)
FI (1)	FI802828A (sv)
FR (1)	FR2464942A1 (sv)
IT (1)	IT1195032B (sv)
NL (1)	NL8005084A (sv)
NO (1)	NO802683L (sv)
SE (1)	SE8006333L (sv)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB924815A (en) *	1959-12-24	1963-05-01	Maurice Roux	Improvements in methods of preparation of polypeptides of spasmolytic activity

1980
- 1980-09-08 DK DK380880A patent/DK380880A/da not_active Application Discontinuation
- 1980-09-09 NL NL8005084A patent/NL8005084A/nl not_active Application Discontinuation
- 1980-09-10 NO NO802683A patent/NO802683L/no unknown
- 1980-09-10 FR FR8019545A patent/FR2464942A1/fr active Granted
- 1980-09-10 SE SE8006333A patent/SE8006333L/sv not_active Application Discontinuation
- 1980-09-10 AT AT0455180A patent/AT373149B/de not_active IP Right Cessation
- 1980-09-10 ES ES494917A patent/ES494917A0/es active Granted
- 1980-09-10 FI FI802828A patent/FI802828A/fi not_active Application Discontinuation
- 1980-09-10 CH CH681480A patent/CH646414A5/de not_active IP Right Cessation
- 1980-09-11 BE BE6/47265A patent/BE885199A/fr not_active IP Right Cessation
- 1980-09-11 DE DE19803034198 patent/DE3034198A1/de not_active Withdrawn
- 1980-09-11 CA CA000360561A patent/CA1160624A/en not_active Expired
- 1980-09-11 JP JP55125375A patent/JPS609760B2/ja not_active Expired
- 1980-09-11 AU AU62317/80A patent/AU537523B2/en not_active Ceased
- 1980-09-11 IT IT24588/80A patent/IT1195032B/it active

Also Published As

Publication number	Publication date
SE8006333L (sv)	1981-03-12
JPS609760B2 (ja)	1985-03-12
JPS56123996A (en)	1981-09-29
IT1195032B (it)	1988-09-28
DE3034198A1 (de)	1981-04-09
FR2464942B1 (sv)	1984-10-26
AU6231780A (en)	1981-03-19
ATA455180A (de)	1983-05-15
NL8005084A (nl)	1981-03-13
FI802828A (fi)	1981-03-12
ES8105699A1 (es)	1981-06-16
ES494917A0 (es)	1981-06-16
CA1160624A (en)	1984-01-17
AU537523B2 (en)	1984-06-28
FR2464942A1 (fr)	1981-03-20
DK380880A (da)	1981-05-12
NO802683L (no)	1981-05-07
BE885199A (fr)	1981-03-11
IT8024588A0 (it)	1980-09-11
AT373149B (de)	1983-12-27

Publication	Publication Date	Title
Ismail et al.	1988	Are the toxicological effects of scorpion envenomation related to tissue venom concentration?
EP0158986B1 (de)	1993-09-15	Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel
DE3855970T2 (de)	1998-01-29	Verwendung von Amylin oder CGRP zur Behandlung des Diabetes mellitus
DE69130289T2 (de)	1999-06-02	Therapeutische verwendung von actin-bindenden verbindungen
EP0167575B1 (de)	1993-05-26	Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US4370317A (en)	1983-01-25	Pancreatic spasmolytic polypeptide
EP0209061A2 (de)	1987-01-21	Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel
DE19908041A1 (de)	2000-08-31	Kovalent verbrückte Insulindimere
DE69737065T2 (de)	2007-06-28	Insulin c-peptide
EP0049847A2 (de)	1982-04-21	Alpha-Amylaseinaktivator, Verfahren zu seiner Herstellung, Mittel auf Basis dieses Inaktivators sowie dieser Inaktivator zur Regulierung des Blutzuckerspiegels
DD296933A5 (de)	1991-12-19	Peptide
DE69830842T2 (de)	2006-05-24	Peptide als kalium kanalaktivatoren
JPS63303930A (ja)	1988-12-12	インシユリンおよびインシユリン誘導体の混合結晶
DE2734150A1 (de)	1978-08-31	Verfahren zur gewinnung von human- lysozym
DE3781268T2 (de)	1993-04-22	Verwendung von wachstumshormonen zur stickstoffzurueckhaltung bei hypokalorischen bedingungen.
DE3421789A1 (de)	1985-12-12	Arzneimittel aus dem thymus und verfahren zu dessen herstellung
Brockman Jr et al.	1957	Multiple nature of inhibitory factor (Factor I) from brain
DE2558537C2 (de)	1984-07-19	Verfahren zum Isolieren von Substanzen mit insulinähnlicher Wirksamkeit aus Blut oder Blutbestandteilen von Kälbern oder Schweinen
DE68928646T2 (de)	1998-08-13	Natriuretisches hormon
CH646414A5 (en)	1984-11-30	Purified pancreatic spasmolytic polypeptide, process for its isolation, and pharmaceutical composition
SU871721A3 (ru)	1981-10-07	Способ получени биологически активного вещества,обладающего способностью усиливать секрецию инсулина и улучшать глюкозную толерантность
DE3443257A1 (de)	1986-05-28	Mittel enthaltend vollsynthetisches alpha-humanes atriales natriuretisches peptid (alpha-hanap)
LU83206A1 (de)	1981-06-24	Gereinigtes polypeptid,verfahren zum isolieren und verwendung desselben sowie pharmazeutische zusammensetzung und waessrige sterile loesung
DE2159923C3 (de)	1974-05-22	Verfahren zur Gewinnung eines Stoffes mit insulinähnlicher Wirkung und diese Stoffe enthaltende Arzneipräparate
US3475534A (en)	1969-10-28	Methods of treating hyperinsulinism

Legal Events

Date	Code	Title	Description
1988-05-31	PL	Patent ceased
2024-10-31	PL	Patent ceased